Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database

Abstract: The U.S. Food and Drug Administration (FDA) has stated that the prescription of remdesivir should be cautious for patients with estimated glomerular filtration rate (eGFR) < 30 and some studies reported risk of adverse renal events. The available information on the renal safety profile...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Nayara Aparecida de Oliveira Silva (Author), Ana Laura de Sene Amâncio Zara (Author), Albert Figueras (Author), Daniela Oliveira de Melo (Author)
Format: Knjiga
Izdano: Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz, 2021-11-01T00:00:00Z.
Teme:
Online dostop:Connect to this object online.
Oznake: Označite
Brez oznak, prvi označite!

Internet

Connect to this object online.

3rd Floor Main Library

Podrobnosti zaloge 3rd Floor Main Library
Signatura: A1234.567
Kopija 1 Prosto